12:00 AM
 | 
Jul 01, 2013
 |  BioCentury  |  Product Development

Antigen round up

Access to new cancer targets key to Genentech deal for Immunocore TCR platform

Based on undisclosed data from an ongoing Phase I trial, Genentech Inc. decided to license rights to a 14-year-old technology that could allow the company to target a broad swath of cancer antigens that are impossible to hit with conventional antibodies and antibody-based strategies like chimeric antigen receptors and antibody-drug conjugates.

Under a deal announced last week, the Roche unit and Immunocore Ltd. will use the latter's technology to discover and develop bi-specific ImmTACs against an undisclosed number of cancer targets.

ImmTACs use soluble monoclonal T cell receptors (TCRs) to hit antigens presented on the surface of tumor cells. The TCRs are fused to an anti-CD3 antibody fragment that recruits killer T cells to the tumor.

Genentech will receive exclusive, worldwide rights to each ImmTAC-target pair for all cancer indications. Immunocore will receive $10-$20 million in upfront fees per pair and is eligible for more than $300 million in milestones, plus tiered royalties.

The deal...

Read the full 766 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >